Guizhou Yibai Pharmaceutical Co., Ltd.

Shanghai Stock Exchange 600594.SS

Guizhou Yibai Pharmaceutical Co., Ltd. Operating Income Margin for the year ending December 31, 2023: 5.24%

Guizhou Yibai Pharmaceutical Co., Ltd. Operating Income Margin is 5.24% for the year ending December 31, 2023, a -44.32% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

Guizhou Yibai Pharmaceutical Co., Ltd. Operating Income Margin for the year ending December 31, 2022 was 9.41%, a -41.27% change year over year.
Guizhou Yibai Pharmaceutical Co., Ltd. Operating Income Margin for the year ending December 31, 2021 was 16.02%, a 12.38% change year over year.
Guizhou Yibai Pharmaceutical Co., Ltd. Operating Income Margin for the year ending December 31, 2020 was 14.26%, a 26.83% change year over year.
Guizhou Yibai Pharmaceutical Co., Ltd. Operating Income Margin for the year ending December 31, 2019 was 11.24%, a 156.10% change year over year.

Key data

Date	Operating Income Margin	EBT Margin	Net Income Margin	EBITDA Margin

Shanghai Stock Exchange: 600594.SS

Guizhou Yibai Pharmaceutical Co., Ltd.

CEO	Ms. Ya Qi Dou
IPO Date	March 23, 2004
Location	China
Headquarters	No. 220-1, Baiyun Avenue
Employees	5,509
Sector	Health Care
Industries Pharmaceuticals Cosmetics

Description

Guizhou Yibai Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China. It offers products in the form of capsules, tablets, granules, syrups, small-volume injections, freeze-dried powder injections, pills, and oral solutions in the areas of tumor system, cerebrovascular, respiratory system, rheumatism, digestive system, pediatric, gynecological, anti-infection, anti-inflammatory, analgesic, and other diseases. The company was founded in 1995 and is based in Guiyang, China.

Key trends

Past 5 years